U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164755) titled 'Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin' on Sept. 02.
Brief Summary: About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial challenges, and a higher risk of suicide.
Psilocybin-a compound found in certain mushrooms-has shown early promise as a new treatment for this difficult-to-treat depression. Scientists believe it works by affecting a specific brain receptor (called 5-HT2A), which helps the brain become m...